{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:31Z","timestamp":1790270731451,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,19]]},"DOI":"10.7759\/cureus.97299","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:55:57Z","timestamp":1763625357000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune-Mediated Thrombocytopenia Induced by Niraparib: A Clinically Relevant Case"],"prefix":"10.7759","author":[{"given":"Fernando","family":"Roxo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delfim","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel H","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn A","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al.. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019, 381:2391-402. 10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza MR","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al.. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016, 375:2154-64. 10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue CJ","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019, 20:e15-28. 10.1016\/S1470-2045(18)30786-1","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management","volume":"7","author":"Aster RH","year":"2009","unstructured":"Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009, 7:911-8. 10.1111\/j.1538-7836.2009.03360.x","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"Marini I","year":"2022","unstructured":"Marini I, Uzun G, Jamal K, Bakchoul T. Treatment of drug-induced immune thrombocytopenias. Haematologica. 2022, 107:1264-77. 10.3324\/haematol.2021.279484","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e85","article-title":"FIGO staging of endometrial cancer: 2023","volume":"34","author":"Berek JS","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C, et al.. FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 2023, 34:e85. 10.3802\/jgo.2023.34.e85","journal-title":"J Gynecol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk BJ","year":"2023","unstructured":"Monk BJ, Gonz\u00e1lez-Martin A, Buckley L, et al.. Safety and management of niraparib monotherapy in ovarian cancer clinical trials. Int J Gynecol Cancer. 2023, 33:971-81. 10.1136\/ijgc-2022-004079","journal-title":"Int J Gynecol Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian X","year":"2022","unstructured":"Tian X, Chen L, Gai D, He S, Jiang X, Zhang N. Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol. 2022, 13:851246. 10.3389\/fphar.2022.851246","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu Y","year":"2023","unstructured":"Shu Y, Ding Y, He X, Liu Y, Wu P, Zhang Q. Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med. 2023, 12:3365-75. 10.1002\/cam4.5062","journal-title":"Cancer Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1542646","article-title":"Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review","volume":"15","author":"Li J","year":"2025","unstructured":"Li J, Yang J, Wang Y. Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review. Front Oncol. 2025, 15:1542646. 10.3389\/fonc.2025.1542646","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5414\/CP204724","article-title":"Niraparib-related severe refractory thrombocytopenia in ovarian cancer patients receiving paclitaxel\/carboplatin chemotherapy: a report on three cases","volume":"63","author":"Chen M","year":"2025","unstructured":"Chen M, Zhou L, Yang H, Wang M. Niraparib-related severe refractory thrombocytopenia in ovarian cancer patients receiving paclitaxel\/carboplatin chemotherapy: a report on three cases. Int J Clin Pharmacol Ther. 2025, 63:169-73. 10.5414\/CP204724","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-2252","article-title":"Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib","volume":"9","author":"Wang J","year":"2021","unstructured":"Wang J, Zhu J. Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib. Ann Transl Med. 2021, 9:869. 10.21037\/atm-21-2252","journal-title":"Ann Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63600-z","article-title":"Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer","volume":"14","author":"Uekusa R","year":"2024","unstructured":"Uekusa R, Yokoi A, Watanabe E, et al.. Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer. Sci Rep. 2024, 14:12595. 10.1038\/s41598-024-63600-z","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu D","year":"2022","unstructured":"Sandhu D, Antolin AA, Cox AR, Jones AM. Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale. Br J Clin Pharmacol. 2022, 88:742-52. 10.1111\/bcp.15015","journal-title":"Br J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.927008","article-title":"Avatrombopag optimizes response to niraparib by managing thrombocytopenia associated with poly-ADP ribose polymerase (PARP) inhibition in ovarian cancer and breast cancer: a case series","volume":"21","author":"Gabrail N","year":"2020","unstructured":"Gabrail N, Smith C. Avatrombopag optimizes response to niraparib by managing thrombocytopenia associated with poly-ADP ribose polymerase (PARP) inhibition in ovarian cancer and breast cancer: a case series. Am J Case Rep. 2020, 21:e927008. 10.12659\/AJCR.927008","journal-title":"Am J Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper N","year":"2019","unstructured":"Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019, 381:945-55. 10.1056\/NEJMcp1810479","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/422494-immune-mediated-thrombocytopenia-induced-by-niraparib-a-clinically-relevant-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:55:59Z","timestamp":1763625359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/422494-immune-mediated-thrombocytopenia-induced-by-niraparib-a-clinically-relevant-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.97299","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}